A Computer Simulation Approach to Assessing Therapeutic Intervention Points for the Prevention of Cytokine-Induced Cartilage Breakdown

To use a novel computational approach to examine the molecular pathways involved in cartilage breakdown and to use computer simulation to test possible interventions for reducing collagen release.

[1]  M Kashiwagi,et al.  TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)* , 2001, The Journal of Biological Chemistry.

[2]  J. Dudhia,et al.  JAK/STAT but Not ERK1/ERK2 Pathway Mediates Interleukin (IL)-6/Soluble IL-6R Down-regulation of Type II Collagen, Aggrecan Core, and Link Protein Transcription in Articular Chondrocytes , 2003, The Journal of Biological Chemistry.

[3]  K. Tanzawa,et al.  Inhibition of ADAMTS4 (aggrecanase‐1) by tissue inhibitors of metalloproteinases (TIMP‐1, 2, 3 and 4) , 2001, FEBS letters.

[4]  Sang-Gu Hwang,et al.  c-Jun/Activator Protein-1 Mediates Interleukin-1β-induced Dedifferentiation but Not Cyclooxygenase-2 Expression in Articular Chondrocytes* , 2005, Journal of Biological Chemistry.

[5]  Samik Ghosh,et al.  Erratum: The Systems Biology Graphical Notation , 2009, Nature Biotechnology.

[6]  A. Schmidt,et al.  Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.

[7]  John C. Lee,et al.  Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. , 1997, Journal of immunology.

[8]  R. Finke,et al.  Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. , 2009, Biochimica et biophysica acta.

[9]  N. Kikuchi,et al.  CellDesigner 3.5: A Versatile Modeling Tool for Biochemical Networks , 2008, Proceedings of the IEEE.

[10]  Darren J. Wilkinson,et al.  Tools for the SBML Community , 2006, Bioinform..

[11]  B. Bresnihan,et al.  Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist , 1999, Annals of the rheumatic diseases.

[12]  U Klingmüller,et al.  Predictive mathematical models of cancer signalling pathways , 2012, Journal of internal medicine.

[13]  J. Rutter,et al.  Synergistic induction of matrix metalloproteinase 1 by interleukin-1alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. , 2001, Arthritis and rheumatism.

[14]  A. Rowan,et al.  Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. , 2003, The American journal of pathology.

[15]  J. Heath,et al.  Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. , 2001, Arthritis and rheumatism.

[16]  G. Lisignoli,et al.  Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. , 2001, Arthritis and rheumatism.

[17]  R. Wait,et al.  Induction of interleukin-1 in articular cartilage by explantation and cutting. , 2004, Arthritis and rheumatism.

[18]  W. Ferrell,et al.  Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. , 2010, Arthritis and rheumatism.

[19]  Melanie I. Stefan,et al.  BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models , 2010, BMC Systems Biology.

[20]  Mudita Singhal,et al.  COPASI - a COmplex PAthway SImulator , 2006, Bioinform..

[21]  D. Hochbaum,et al.  Phosphorylation of c-Fos by Members of the p38 MAPK Family , 2005, Journal of Biological Chemistry.

[22]  J. Raynauld,et al.  Quantitative imaging of the structural changes of osteoarthritis: An exciting challenge for the new millennium , 2001, Current rheumatology reports.

[23]  D. Zukor,et al.  Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. , 2005, Arthritis and rheumatism.

[24]  P. Linsley,et al.  Identification and characterization of cellular receptors for the growth regulator, oncostatin M. , 1989, The Journal of biological chemistry.

[25]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[26]  M. Goldring,et al.  The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. , 1998, Arthritis and rheumatism.

[27]  Sarala M. Wimalaratne,et al.  The Systems Biology Graphical Notation , 2009, Nature Biotechnology.

[28]  T E Cawston,et al.  Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. , 2001, Arthritis and rheumatism.

[29]  A. Rowan,et al.  Collagenase gene regulation by pro-inflammatory cytokines in cartilage. , 2007, Frontiers in bioscience : a journal and virtual library.

[30]  C. Brinckerhoff,et al.  Matrix metalloproteinases: role in arthritis. , 2006, Frontiers in bioscience : a journal and virtual library.

[31]  Darren J. Wilkinson.  Stochastic Modelling for Systems Biology , 2006 .

[32]  M. Sporn,et al.  The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes , 2003, Arthritis research & therapy.

[33]  A. Rowan,et al.  Synergistic Collagenase Expression and Cartilage Collagenolysis Are Phosphatidylinositol 3-Kinase/Akt Signaling-dependent* , 2008, Journal of Biological Chemistry.

[34]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[35]  T. Cawston,et al.  Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. , 2005, Current drug targets. Inflammation and allergy.

[36]  C. Sen,et al.  Antioxidant and redox regulation of gene transcription , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  A. Rowan,et al.  Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. , 2006, Arthritis and rheumatism.

[38]  D. Edwards,et al.  The Human Tissue Inhibitor of Metalloproteinases (TIMP)-1 Gene Contains Repressive Elements within the Promoter and Intron 1* , 2000, The Journal of Biological Chemistry.

[39]  D. Noble.  Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[40]  D. Gillespie.  Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .

[41]  P. Heinrich,et al.  Oncostatin M Receptor-mediated Signal Transduction Is Negatively Regulated by SOCS3 through a Receptor Tyrosine-independent Mechanism* , 2006, Journal of Biological Chemistry.